Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Thomas Yorio, Gaurang C. Patel & Abbot F. Clark. (2020) Glucocorticoid-induced ocular hypertension: origins and new approaches to minimize. Expert Review of Ophthalmology 15:3, pages 145-157.
Read now
Read now
Ahmed Samir, Ayano Kage, Kayoko Ohura & Teruko Imai. (2019) Development of simultaneous quantification method of loteprednol etabonate (LE) and its acidic metabolites, and analysis of LE metabolism in rat. Xenobiotica 49:5, pages 569-576.
Read now
Read now
Carlo Alberto Cutolo, Stefano Barabino, Chiara Bonzano & Carlo Enrico Traverso. (2019) The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. Ocular Immunology and Inflammation 27:2, pages 266-275.
Read now
Read now
Mahmoud A Khaimi. (2018) A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty. Clinical Ophthalmology 12, pages 319-329.
Read now
Read now
Timothy L. Comstock & John D. Sheppard. (2018) Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opinion on Pharmacotherapy 19:4, pages 337-353.
Read now
Read now
Timothy L. Comstock & Heleen H. DeCory. (2017) Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis. Ocular Immunology and Inflammation 25:2, pages 267-274.
Read now
Read now
Pranjal Taskar, Akshaya Tatke & Soumyajit Majumdar. (2017) Advances in the use of prodrugs for drug delivery to the eye. Expert Opinion on Drug Delivery 14:1, pages 49-63.
Read now
Read now
Clifford L Salinger, Michael Gordon, Mitchell A Jackson, Theodore Perl & Eric Donnenfeld. (2015) A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Clinical Ophthalmology 9, pages 2089-2097.
Read now
Read now
Lian-Qun Wu, Xu Chen, Heng Lou, Jin-Wei Cheng & Rui-Li Wei. (2015) Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis. Current Medical Research and Opinion 31:8, pages 1509-1518.
Read now
Read now
Amir Pirouzian & E Randy Craven. (2014) Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery. Clinical Ophthalmology 8, pages 379-387.
Read now
Read now
Martin J Coffey, Heleen H DeCory & Stephen S Lane. (2013) Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clinical Ophthalmology 7, pages 299-312.
Read now
Read now
Raymond Fong, Martin Leitritz, Raphaele Siou-Mermet & Tara Erb. (2012) Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clinical Ophthalmology 6, pages 1113-1124.
Read now
Read now
Minjie Chen, Lan Gong, Xinghuai Sun, Yangshun Gu, Xiangge He, Jia Qu, Lili Wang, Mingzhi Zhang & Xingwu Zhong. (2012) A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current Medical Research and Opinion 28:3, pages 385-394.
Read now
Read now
Timothy L Comstock, Michael R Paterno, Angele Singh, Tara Erb & Elizabeth Davis. (2011) Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clinical Ophthalmology 5, pages 177-186.
Read now
Read now
Timothy L Comstock & Edward J Holland. (2010) Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opinion on Pharmacotherapy 11:5, pages 843-852.
Read now
Read now
Mayssa Attar, Jie Shen, Kah-Hiing John Ling & Diane Tang-Liu. (2005) Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters. Expert Opinion on Drug Delivery 2:5, pages 891-908.
Read now
Read now
Nicholas Bodor & Peter Buchwald. (2001) DRUG TARGETING BY RETROMETABOLIC DESIGN: SOFT DRUGS AND CHEMICAL DELIVERY SYSTEMS. Journal of Receptors and Signal Transduction 21:2-3, pages 287-310.
Read now
Read now
Nicholas Bodor, Nicole Bodor & Whei-Mei Wu. (1992) A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Current Eye Research 11:6, pages 525-530.
Read now
Read now
Articles from other publishers (54)
Hasan Razmjoo, Mohammad Mikaniki, Alireza Peyman, Ebrahim Mikaniki, Mahdi Abounoori & Mohsen Pourazizi. (2022) Clinical efficacy of Fluorometholone versus Loteprednol eye drops after photorefractive keratectomy: A triple-blinded randomized controlled trial. European Journal of Ophthalmology 33:1, pages 595-601.
Crossref
Crossref
Kyle E. Kline, Stuart A. Walton, Andrew J. Specht, Domenico Santoro, Travis J. Watson, Megan L. Eide, Taylor A. Opgenorth & Caryn E. Plummer. (2022)
Comparison of ophthalmic loteprednol etabonate and prednisolone acetate effects on adrenocortical response to
ACTH
in dogs
. Veterinary Ophthalmology.
Crossref
Crossref
Eva M. del Amo, Anam Hammid, Melanie Tausch, Elisa Toropainen, Amir Sadeghi, Annika Valtari, Jooseppi Puranen, Mika Reinisalo, Marika Ruponen, Arto Urtti, Achim Sauer & Paavo Honkakoski. (2022) Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations. International Journal of Pharmaceutics 613, pages 121361.
Crossref
Crossref
Elizabeth J. Feuille, Wanda Phipatanakul & Perdita Permaul. 2022. Allergic and Immunologic Diseases. Allergic and Immunologic Diseases
1077
1109
.
Sherif A. Gaballa, Uday B. Kompella, Omar Elgarhy, Ali M. Alqahtani, Barbara Pierscionek, Raid G. Alany & Hamdy Abdelkader. (2020) Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Delivery and Translational Research 11:3, pages 866-893.
Crossref
Crossref
Michael Korenfeld, Kelly K. Nichols, Damien Goldberg, David Evans, Ken Sall, Gary Foulks, Susan Coultas & Kim Brazzell. (2021) Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies. Cornea 40:5, pages 564-570.
Crossref
Crossref
Anam Hammid, John K. Fallon, Toni Lassila, Giulia Salluce, Philip C. Smith, Ari Tolonen, Achim Sauer, Arto Urtti & Paavo Honkakoski. (2021) Carboxylesterase Activities and Protein Expression in Rabbit and Pig Ocular Tissues. Molecular Pharmaceutics 18:3, pages 1305-1316.
Crossref
Crossref
Tek Chand & Arvind Chauhan. (2020) A comparative study of the efficacy of preoperative loteprednol versus flurbiprofen in cataract surgery. Indian Journal of Clinical and Experimental Ophthalmology 6:4, pages 581-586.
Crossref
Crossref
Mohammud G Musleh, Desta Bokre & Annegret H Dahlmann-Noor. (2019) Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic review. European Journal of Ophthalmology 30:5, pages 856-866.
Crossref
Crossref
Kenneth BeckmanJames KatzParag MajmudarAudrey Rostov. (2020) Loteprednol Etabonate for the Treatment of Dry Eye Disease. Journal of Ocular Pharmacology and Therapeutics 36:7, pages 497-511.
Crossref
Crossref
Yung Ju YooHee Kyung YangJeong-Min Hwang. (2018) Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children. Journal of Ocular Pharmacology and Therapeutics 34:6, pages 468-476.
Crossref
Crossref
John D. Sheppard, Timothy L. Comstock & Megan E. Cavet. (2016) Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Advances in Therapy 33:4, pages 532-552.
Crossref
Crossref
Stacey Ackerman, Lisa M. Smith & Paulo J. Gomes. (2016) Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Therapeutic Advances in Chronic Disease 7:1, pages 52-67.
Crossref
Crossref
Hun Lee, Byunghoon Chung, Kyu Seo Kim, Kyoung Yul Seo, Bong Joon Choi & Tae-im Kim. (2014) Effects of Topical Loteprednol Etabonate on Tear Cytokines and Clinical Outcomes in Moderate and Severe Meibomian Gland Dysfunction: Randomized Clinical Trial. American Journal of Ophthalmology 158:6, pages 1172-1183.e1.
Crossref
Crossref
Lisa Schopf, Elizabeth Enlow, Alexey Popov, James Bourassa & Hongming Chen. (2014) Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation. Ophthalmology and Therapy 3:1-2, pages 63-72.
Crossref
Crossref
Emrullah BeyazyıldızUğur AcarÖzlem BeyazyıldızFerda Alparslan PınarlıAynur AlbayrakNagihan UğurluMeral TiryakiTuncay Delibaşi. (2014) Comparison of Prednisolone Acetate and Loteprednol Etabonate for the Treatment of Benzalkonium Chloride-Induced Dry Eye Syndrome in Rats. Journal of Ocular Pharmacology and Therapeutics 30:4, pages 306-312.
Crossref
Crossref
Vladimir Dobričić, Bojan Marković, Katarina Nikolic, Vladimir Savić, Sote Vladimirov & Olivera Čudina. (2014) 17β-carboxamide steroids – in vitro prediction of human skin permeability and retention using PAMPA technique. European Journal of Pharmaceutical Sciences 52, pages 95-108.
Crossref
Crossref
Stephen S. Lane & Edward J. Holland. (2013) Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. Journal of Cataract and Refractive Surgery 39:2, pages 168-173.
Crossref
Crossref
Rajesh K. Rajpal, Lawrence Roel, Raphaele Siou-Mermet & Tara Erb. (2013) Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. Journal of Cataract and Refractive Surgery 39:2, pages 158-167.
Crossref
Crossref
Kishore Cholkar, Aswani Dutt Vadlapudi, Hoang M. Trinh & Ashim K. Mitra. 2014. Ocular Pharmacology and Toxicology. Ocular Pharmacology and Toxicology
91
118
.
Nicholas Bodor & Peter Buchwald. 2012. Retrometabolic Drug Design and Targeting. Retrometabolic Drug Design and Targeting
77
258
.
Veysi Öner, Fatih Mehmet Türkcü, Mehmet Taş, Mehmet Fuat Alakuş & Yalçın İşcan. (2012) Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety. Japanese Journal of Ophthalmology 56:4, pages 312-318.
Crossref
Crossref
Lan Gong, Xinghuai Sun, Jia Qu, Lili Wang, Mingzhi Zhang, Hong Zhang, Linnong Wang, Yangshun Gu, Albert Elion-Mboussa, Lipika Roy & Byron Zhu. (2012) Loteprednol Etabonate Suspension 0.2% Administered QID Compared With Olopatadine Solution 0.1% Administered BID in the Treatment of Seasonal Allergic Conjunctivitis: A Multicenter, Randomized, Investigator-Masked, Parallel Group Study in Chinese Patients. Clinical Therapeutics 34:6, pages 1259-1272.e1.
Crossref
Crossref
Timothy L. Comstock, Michael R. Paterno, Kirk M. Bateman, Heleen H. DeCory & Matthew Gearinger. (2012) Safety and Tolerability of Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension in Pediatric Subjects. Pediatric Drugs 14:2, pages 119-130.
Crossref
Crossref
Timothy L. Comstock & Heleen H. DeCory. (2012) Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate. International Journal of Inflammation 2012, pages 1-11.
Crossref
Crossref
Donald J. AbrahamNicholas Bodor & Peter Buchwald. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
73
190
.
Whei-Mei Wu, Fenglei Huang, Yangsuk Lee, Peter Buchwald & Nicholas Bodor. (2008) Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats. Journal of Pharmacy and Pharmacology 60:3, pages 291-297.
Crossref
Crossref
P.-Y. Robert. 2010. Les Uvéites. Les Uvéites
611
616
.
Edward J Holland, Ali R Djalilian & Jeffrey P Sanderson. (2009) Attenuation of Ocular Hypertension With the Use of Topical Loteprednol Etabonate 0.5% in Steroid Responders After Corneal Transplantation. Cornea 28:10, pages 1139-1143.
Crossref
Crossref
M. Omar F. Khan & Henry J. Lee. (2008) Synthesis and Pharmacology of Anti-Inflammatory Steroidal Antedrugs. Chemical Reviews 108:12, pages 5131-5145.
Crossref
Crossref
Edward J Holland, Jimmy D Bartlett, Michael R Paterno, Dale W Usner & Timothy L Comstock. (2008) Effects of Loteprednol/Tobramycin Versus Dexamethasone/Tobramycin on Intraocular Pressure in Healthy Volunteers. Cornea 27:1, pages 50-55.
Crossref
Crossref
Nicholas Bodor & Peter Buchwald. (2005) Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. The AAPS Journal 7:4, pages E820-E833.
Crossref
Crossref
Shin-ichi Yasueda, Masayo Higashiyama, Yoshihisa Shirasaki, Katsuhiro Inada & Akira Ohtori. (2004) An HPLC method to evaluate purity of a steroidal drug, loteprednol etabonate. Journal of Pharmaceutical and Biomedical Analysis 36:2, pages 309-316.
Crossref
Crossref
Robert Hermann, Mathias Locher, Marianne Siebert-Weigel, Nicole LaVallee, Hartmut Derendorf & Günther Hochhaus. (2004) Intranasal Loteprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. The Journal of Clinical Pharmacology 44:5, pages 510-519.
Crossref
Crossref
Haroon Ilyas, Charles B. Slonim, Guy R. Braswell, John R. Favetta & Melvin Schulman. (2004) Long-term Safety of Loteprednol Etabonate 0.2% in the Treatment of Seasonal and Perennial Allergic Conjunctivitis. Eye & Contact Lens: Science & Clinical Practice 30:1, pages 10-13.
Crossref
Crossref
Yoshihisa Shirasaki, Katsuhiro Inada, Jun Inoue & Masayuki Nakamura. (2004) Isolation and structure elucidation of the major photodegradation products of loteprednol etabonate. Steroids 69:1, pages 23-34.
Crossref
Crossref
Donald J. AbrahamNicholas Bodor & Peter Buchwald. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
533
608
.
Charles N.J. Mcghee, Simon Dean & Helen Danesh-Meyer. (2002) Locally Administered Ocular Corticosteroids. Drug Safety 25:1, pages 33-55.
Crossref
Crossref
Nicholas Bodor & Peter Buchwald. 2001. Drug Targeting Technology. Drug Targeting Technology.
Nicholas Bodor & Peter Buchwald. (2000) Soft drug design: General principles and recent applications. Medicinal Research Reviews 20:1, pages 58-101.
Crossref
Crossref
N Bodor. (1999) Recent advances in retrometabolic design approaches. Journal of Controlled Release 62:1-2, pages 209-222.
Crossref
Crossref
. (1999) Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. American Journal of Ophthalmology 127:5, pages 537-544.
Crossref
Crossref
David G Shulman, Larry L Lothringer, Jay M Rubin, Richard B Briggs, John Howes, Gary D Novack & Kathryn Hart. (1999) A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis11None of the investigators had a proprietary interest in loteprednol etabonate.. Ophthalmology 106:2, pages 362-369.
Crossref
Crossref
N. Bodor, P. Buchwald & M.-J. Huang. 1999. Computational Molecular Biology. Computational Molecular Biology
569
618
.
Robert Stewart, Barry Horwitz, John Howes, Gary D. Novack & Kathryn Hart. (1998) Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation. Journal of Cataract and Refractive Surgery 24:11, pages 1480-1489.
Crossref
Crossref
Steven J. Dell, George M. Lowry, James A. Northcutt, John Howes, Gary D. Novack & Kathryn Hart. (1998) A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology 102:2, pages 251-255.
Crossref
Crossref
JOHN HOWES & GARY D. NOVACK. (1998) Failure to Detect Systemic Levels, and Effects of Loteprednol Etabonate and its Metabolite, PJ-91, Following Chronic Ocular Administration. Journal of Ocular Pharmacology and Therapeutics 14:2, pages 153-158.
Crossref
Crossref
STEVEN J. DELL, DAVID G. SHULMAN, GEORGE M. LOWRY & JOHN HOWES. (1997) A Controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Prophylactic Treatment of Seasonal Allergic Conjunctivitis. American Journal of Ophthalmology 123:6, pages 791-797.
Crossref
Crossref
MITCHELL H. FRIEDLAENDER & JOHN HOWES. (1997) A Double-masked, Placebo-controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Treatment of Giant Papillary Conjunctivitis. American Journal of Ophthalmology 123:4, pages 455-464.
Crossref
Crossref
Stanislaw Rachwal, Emil Pop & Marcus E. Brewster. (1996) Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques. Steroids 61:9, pages 524-530.
Crossref
Crossref
Guenther Hochhaus, Pascal Druzgala, John F. Howes, Nicholas Bodor & Hartmut Derendorf. (1994) Response to the Commentary on “Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs”. Journal of Pharmaceutical Sciences 83:7, pages 1067-1068.
Crossref
Crossref
Thorsteinn Loftsson & Nicholas Bodor. (1994) The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids. Advanced Drug Delivery Reviews 14:2-3, pages 293-299.
Crossref
Crossref
G.C. Visor. (1994) Drug design strategies for ocular therapeutics. Advanced Drug Delivery Reviews 14:2-3, pages 269-279.
Crossref
Crossref
Indra K. Reddy & Nicholas S. Bodor. (1994) Novel approaches to design and deliver safe and effective antiglaucoma agents to the eye. Advanced Drug Delivery Reviews 14:2-3, pages 251-267.
Crossref
Crossref